Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome.
A patient is described with clinical and laboratory evidence of von Willebrand's disease (VWD) in association with lymphosarcoma. He consistently had a bleeding time of over 20 min; factor VIIAHF, VIIAGN, and VIIVWF under 20%; and severe, diffuse hemorrhage, Following transfusion with cryoprecipitate, the patient had the expected rise in VIIAGN and VIIAHF. The patient's plasma contained an inhibitor which prevented aggregation of normal platelets by ristocetin, but which did not interfere with the measurement of VIIAGN or inactivate VIIAHF activity. The inhibitor was present in serum heated at 56 degrees C for 30 min, was present in a purified IgG fraction of serum, and was precipitated by anti-human IgG. The antibody did not interact directly with washed platelets, but appeared to interact with that portion of the factor VII protein that supports ristocetin aggregation (VIIIVWF). The data provide the first explanation for the pathophysiology of the acquired von Willebrand's syndrome.
D000906:Antibodies / Q000032:analysis; D000918:Antibody Specificity; D001792:Blood Platelets / Q000276:immunology; D011232:Chemical Precipitation; D003080:Cold Temperature; D003450:Cryoglobulins / Q000627:therapeutic use; D005167:Factor VII / Q000037:antagonists & inhibitors*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D013577:Syndrome; D014842:von Willebrand Diseases / Q000097:blood / Q000276:immunology*
D000906:Antibodies; D003450:Cryoglobulins; D007074:Immunoglobulin G; D005167:Factor VII